Results 81 to 90 of about 79,213 (303)

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma

, 2018
Background: Intrahepatic cholangiocarcinoma with hepatic hilus involvement has been either classified as intrahepatic cholangiocarcinoma or hilar cholangiocarcinoma.
Chen QY, Popescu I, Aldrighetti L, Maithel SK, Soubrane O, Poultsides GA, Lv Y, Guglielmi A, Koerkamp BG, Bagante F, Marques HP, Shen F, Pawlik TM, Bauer TW, Martel G, Zhang XF, Pulitano C, Beal EW, Itaru E, Weiss M   +19 more
core   +2 more sources

Immunobiology of cholangiocarcinoma [PDF]

JHEP Reports, 2019
Cholangiocarcinoma (CCA) represents a heterogeneous group of epithelial tumours that are classified according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Although surgical resection and liver transplantation following neoadjuvant therapy are potentially curative options for a subset of patients with early-stage ...
Emilien Loeuillard, Caitlin B. Conboy, Gregory J. Gores, Sumera Rizvi   +3 more
openaire   +3 more sources

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma

JCO Global Oncology, 2020
PURPOSE Cholangiocarcinoma (CCA) remains a disease with poor prognosis and limited therapeutic options. Identification of driver genetic alterations may lead to the discovery of more effective targeted therapies.
Sarinya Kongpetch, Apinya Jusakul, Jing Quan Lim, Cedric Chuan Young Ng, Jason Yongsheng Chan, Vikneswari Rajasegaran, Tse Hui Lim, Kiat Hon Lim, Su Pin Choo, Simona Dima, Irinel Popescu, Dan G. Duda, Veerapol Kukongviriyapan, Narong Khuntikeo, Chawalit Pairojkul, Steven G. Rozen, Patrick Tan, Bin Tean Teh   +17 more
doaj   +1 more source

Advanced In Vitro Platforms for Experimental Liver Research: From Organoids and Liver‐on‐Chip to Omics and Artificial Intelligence

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate ...
Seyedeh Kiana Teymorian, Pedram Asadi Sarabi, Abbas Piryaei, Massoud Vosough   +3 more
wiley   +1 more source

Nationwide treatment and outcomes of intrahepatic cholangiocarcinoma [PDF]

, 2023
Background: Most data on the treatment and outcomes of intrahepatic cholangiocarcinoma (iCCA) derives from expert centers. This study aimed to investigate the treatment and outcomes of all patients diagnosed with iCCA in a nationwide cohort.
Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG), MS Hematologie   +1 more
core  

Descriptive epidemiology of cholangiocarcinoma in Italy

, 2010
BACKGROUND: Very little data exist on the epidemiology of cholangiocarcinoma in Italy. AIM: We focus on the descriptive epidemiology of cholangiocarcinoma in Italy.
Alvaro D, Crocetti E, FERRETTI, Stefano, Bragazzi MC, Capocaccia R, AISF Cholangiocarcinoma committee   +5 more
core  

Precision medicine in cholangiocarcinoma

, 2018
Cholangiocarcinoma is one of the epithelial cancers with the poorest prognosis and the narrowest therapeutic choice in humans. Compared with other cancer types, cholangiocarcinoma has been often neglected by oncology and liver research studies, thereby ...
PELLINO, ANTONIO, Guido, Maria, Fabris, Luca, Fassan, Matteo, Dadduzio, Vincenzo, Cillo, Umberto, Indraccolo, Stefano, Loupakis, Fotios, Cadamuro, Massimiliano   +8 more
core   +1 more source

Hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma incidence trends, 1998–2009.

, 2015
aAPC = annual percent change.bAAPC = average annual percent change.*Significant at ...
Zaria Tatalovich (716644), Katherine A. McGlynn (477287), Alicia I. Rolin (716641), Zhaohui Zou (716643), Jessica L. Petrick (716640), Sean F. Altekruse (583359), James E. Cuccinelli (716642)   +6 more
core   +1 more source